Gene · 5336
Papers3,625
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,625
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The effects of semaphorin 3A in bone and cartilage metabolism: fundamental mechanism and clinical potential. | Front Cell Dev Biol | 2023 | 38078001 | PubTator, text mining | PubMed |
| Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials. | Front Immunol | 2023 | 38077330 | PubTator, text mining | PubMed |
| Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses. | Respir Res | 2023 | 38057814 | PubTator, text mining | PubMed |
| Refractory Status Epilepticus Associated With a Pathogenic Variant in TNFRSF13B. | Cureus | 2023 | 38054159 | PubTator, text mining | PubMed |
| Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. | Eur J Med Res | 2023 | 38053150 | PubTator, text mining | PubMed |
| Genomic characterization of an esthesioneuroblastoma with spinal metastases: illustrative case. | J Neurosurg Case Lessons | 2023 | 38048560 | PubTator, text mining | PubMed |
| Single-cell transcriptomic analysis of corneal organoids during development. | Stem Cell Reports | 2023 | 38039970 | PubTator, text mining | PubMed |
| Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders. | Haematologica | 2023 | 38037802 | PubTator, text mining | PubMed |
| Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study. | Front Med (Lausanne) | 2023 | 38034538 | PubTator, text mining | PubMed |
| Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease. | Cell Mol Biol Lett | 2023 | 38031028 | PubTator, text mining | PubMed |
Myeloid/Lymphoid Neoplasms with ETV6::PDGFRB Fusion Gene: A Rare Case of Poor Response to Imatinib and Possible Transformation Mechanisms from Myeloid Neoplasms of Bone Marrow to T-Cell Lymphoblastic Lymphoma Invasion in Lymph Nodes. | J Inflamm Res | 2023 | 38026242 | PubTator, text mining | PubMed |
| Leveraging iPSC technology to assess neuro-immune interactions in neurological and psychiatric disorders. | Front Psychiatry | 2023 | 38025464 | PubTator, text mining | PubMed |
| SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease. | Alzheimers Dement (N Y) | 2023 | 38023622 | PubTator, text mining | PubMed |
| The implication of next-generation sequencing in the diagnosis and clinical management of non-Hodgkin lymphomas. | Front Oncol | 2023 | 38023160 | PubTator, text mining | PubMed |
| Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity. | Front Immunol | 2023 | 38022590 | PubTator, text mining | PubMed |
| Emerging Alzheimer's disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions. | Front Aging Neurosci | 2023 | 38020773 | PubTator, text mining | PubMed |
| Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer's disease. | Mol Neurodegener | 2023 | 38017562 | PubTator, text mining | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| Application of a dried blood spot based proteomic and genetic assay for diagnosing hereditary angioedema. | Clin Transl Allergy | 2023 | 38006386 | PubTator, text mining | PubMed |
| Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches. | Cancers (Basel) | 2023 | 38001644 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5336/papers?page=15